Simone Fishburn 🎗️

Editor in Chief @BioCentury. Dr, the Ph.D-type. Biotech innovation & breaking barriers, one woman at a time. Views are mine, hope to make them yours too.

[Simone Fishburn 🎗️ @FishburnSimone]

Kicking off 2025 by leaving this platform pretty much for good. Come on over and find me at the other place. @fishburnsimone.bsky.social. You can find there my message to biotechs for the new year. Also on Linkedin https://t.co/yrLsrdGlxk.

[Simone Fishburn 🎗️ @FishburnSimone]

So often I hear, “my vote doesn’t make a difference- I’m in a blue/red state.” Not true. The Iowa poll shows that. States change when people turn up. Don’t leave your fate - or democracy - to others.

Vote.

[Simone Fishburn 🎗️ @FishburnSimone]

I'll be at @fishburnsimone.bsky.social. Come on over.

[Simone Fishburn 🎗️ @FishburnSimone]

Before I fully go to @bluesky, a message for everywhere:
VOTE. Vote like it matters, because it does. Get other people to vote. And most of all, take your kids to vote. Not less important than soccer practice, baseball games or Halloween. Vote.

[Simone Fishburn 🎗️ @FishburnSimone]

Before I fully go to @bluesky, a message for everywhere:
VOTE. Vote like it matters, because it does. Get other people to vote. And most of all, take your kids to vote. Not less important than soccer practice, baseball games or Halloween. Vote.

[Simone Fishburn 🎗️ @FishburnSimone]

And so, with heavy hearts we enter this Jewish New Year. And with more uncertainty and sadness than we have collectively felt for decades. But still the inevitable hope that this will mark a pivot to better days - wishing those who mark it, a good, healthy and peaceful Shana Tova

[Simone Fishburn 🎗️ @FishburnSimone]

There's a long-standing discussion about whether research should be hypothesis-driven or hypothesis free. Omics are making unbiased discovery more realistic and industry is opening up to that. But academic incentives aren't aligned. @_Ktktktktk discusses: https://t.co/Iv5h3aIk2r

[Simone Fishburn 🎗️ @FishburnSimone]

I had a fantastic conversation too! @johnvoyler occupies a rare position in biotech of having built a $20B+ company in under 15 years. Some of his lessons, via the podcast (available also on Apple, Spotify and more).

[John V. Oyler @johnvoyler]

I had a fantastic conversation with @FishburnSimone on the @BioCentury podcast. Thank you for having me as a guest. I truly enjoyed discussing @BeiGeneGlobal's global growth strategy and sharing insights about our innovative pipeline. Full podcast here: https://t.co/AKLJUumyW5

[BeOne Medicines @BeOneMedicines]

Our Co-Founder, Chairman and CEO, @johnvoyler, recently joined @FishburnSimone on the @BioCentury podcast. They delved into BeiGene's corporate global growth and our innovative pipeline. Tune in to the show to discover more: https://t.co/RIau9L0sF9

[BioCentury @BioCentury]

The value in mapping genetics to the medical phenome: case studies from @VanderbiltU. Nancy Cox discusses insights from longitudinal EHRs, biobank data, and their value to drug developers: a BioCentury Q&A https://t.co/JISlOqKoj0

[BioCentury @BioCentury]

John Oyler’s long game at @BeiGeneGlobal: Owning the process from clinical trials to manufacturing. The oncology company's CEO sits down with BioCentury Editor in Chief @FishburnSimone to talk company building and what's next for BeiGene https://t.co/dnv307PGbo

[Regeneron Genetics Center @RegeneronDNA]

@BioCentury We’re inspired by @Immunoplayers in his fireside chat about our joint Together for CHANGE initiative to address data and workforce gaps: "This is a dream project to bring together everyone — all pharma, academic partners are invited to join… First we have to build that trust."

[Regeneron Genetics Center @RegeneronDNA]

RGC’s Gonçalo Abecasis lent his insights during an enlightening panel discussion at @BioCentury Grand Rounds on optimizing data for purpose. He shared that at RGC, “We are big believers that genetic variation leads to good therapies.” #BioCenturyGrandRounds 🧬

[Jeffrey Flier @jflier]

This Harvard student speaks the truth. “Zionist” is not a slur. @Harvard students need to stop using it as one. ⁦@thecrimson⁩ https://t.co/Uo0rFbXpAn

[Simone Fishburn 🎗️ @FishburnSimone]

@DShaywitz @BioCentury @DanielJDrucker I wouldn’t call this hype. More like an analysis of where things are headed. https://t.co/4is5ZI7gLy

[BioCentury @BioCentury]

Introducting BioCentury's Back to School 2024. Editor in Chief @FishburnSimone and colleagues drill down on picking the right target, and ask can industry solve its biggest bottleneck? https://t.co/BFEiDMiETz

[David Axelrod @davidaxelrod]

What a heart-wrenching presentation at the DNC by the parents of Hersh Goldberg-Polin, the young hostage currently being held by Hamas in Gaza.
"There is a surplus of agony on all sides of the tragic conflict in the Middle East. In a competition of pain, there are no winners."

[BioCentury @BioCentury]

Building up B cells @Biogen — Jane Grogan discusses her plans for research at the biotech with @FishburnSimone on The #BioCenturyShow https://t.co/RhDSbrqT5c

[Jeff Cranmer @jeff_cranmer]

In an exclusive conversation with @BioCentury, Jim Wilson describes how he plans to use newly launched GemmaBio as a vehicle to create a sustainable model for ultrarare disease gene therapies by capitalizing on efficiencies gained from a platform model. https://t.co/0XW9SDNIel

[Simone Fishburn 🎗️ @FishburnSimone]

Calling on translational academics! Do you find it hard to meet #biotech VCs and pharmas? Do you have results and an idea that you'd like to showcase?
BioCentury's Grand Rounds conference is designed for you.
Sept 9-11, Nashville, TN.
Find out more: https://t.co/Oiod4taCdY